Holen Sie sich die Stockscreener-App
13.94
7.07%
0.92
Handel nachbörslich:
13.67
-0.27
-1.94%
Schlusskurs vom Vortag:
$13.02
Offen:
$13.18
24-Stunden-Volumen:
702.32K
Relative Volume:
1.54
Marktkapitalisierung:
$969.90M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-9.2318
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+12.33%
1M Leistung:
+4.50%
6M Leistung:
-4.65%
1J Leistung:
+36.27%
1-Tages-Spanne:
$13.06
$14.05
1-Wochen-Bereich:
$11.51
$14.05
52-Wochen-Spanne:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
13.94 | 942.15M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression - MSN
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Ariva
Zymeworks Strengthens Leadership with New Board Appointments - TipRanks
Zymeworks Expands Board with Financial Veterans Greg Ciongoli and Robert E. Landry - The Indian Awaaz
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry | ZYME Stock News - GuruFocus
Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors - Quiver Quantitative
Zymeworks appoints two new directors to strengthen board By Investing.com - Investing.com Nigeria
Zymeworks appoints two new directors to strengthen board - Investing.com
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Will breakout in Zymeworks Inc. lead to full recoveryFree Breakout Entry Signal Confirmation Tool - Newser
Has Zymeworks Inc. formed a bullish divergenceLow Risk Stock Selection Strategy Guide - Newser
Zymeworks Inc. stock trendline breakdownFree Scalable Portfolio Growth Suggestions - Newser
Zymeworks (NASDAQ:ZYME) Announces Earnings Results - MarketBeat
Zymeworks Inc. stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - simplywall.st
Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Is Zymeworks Inc. forming a breakout patternDouble Capital Strategy Picks - thegnnews.com
Can Zymeworks Inc. hit a new high this monthFree Proven Entry Plan With Low Risk Trade - Newser
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Applying sector rotation models to Zymeworks Inc.Technical Reversal Setup with Risk Limits - Newser
What does recent volatility data suggest for Zymeworks Inc.Stock Price Prediction Using AI Tools - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser
Is Zymeworks Inc. affected by consumer sentimentStock Picks with 300% Gain - sisaissue.com
Zymeworks Q2 2025 Earnings Call: Capitalizing on Platform-Driven Innovation and Strategic Execution - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (NASDAQ:ZYME) Lowered to “Hold” Rating by Wall Street Zen - Defense World
Zymeworks Reports Strong Q2 2025 Financial Performance - The Globe and Mail
Zymeworks Reports Q2 Results and FDA Clearance - The Globe and Mail
Transcript : Zymeworks Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Zymeworks Inc. 2025 Q2 Earnings and Strategic Progress: A Catalyst for Oncology Innovation and Shareholder Value - AInvest
Zymeworks: Unleashing Long-Term Value Through Royalty-Driven Growth and Strategic Pipeline Execution - AInvest
Zymeworks Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ZYME) - Seeking Alpha
Earnings call transcript: Zymeworks sees revenue surge in Q2 2025 By Investing.com - Investing.com Nigeria
Earnings call transcript: Zymeworks sees revenue surge in Q2 2025 - Investing.com
Zymeworks Q2 2025 presentation: Revenue quadruples, pipeline advances with new IND - Investing.com Nigeria
Zymeworks Inc (ZYME) Q2 2025 Earnings Call Highlights: Revenue S - GuruFocus
Zymeworks Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Zymeworks Turns The Corner With Strong Q2 Results And Partnerships - Finimize
Zymeworks Reports Q2 Earnings, FDA Clearance, and Revenue Growth - AInvest
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mln - MarketScreener
When is the best time to exit Zymeworks Inc.Free Multi-Bagger Potential Stock Forecast Tools - Newser
Cwm LLC Increases Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Thursday - Defense World
Zymeworks Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Envestnet Asset Management Inc. Sells 4,578 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
What is the dividend policy of Zymeworks Inc. stockTriple-digit return opportunities - Jammu Links News
What drives Zymeworks Inc. stock priceStay ahead with daily expert stock picks - Jammu Links News
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):